FGF21, fibroblast growth factor 21, 26291

N. diseases: 236; N. variants: 2
Disease: Fatty Liver Disease ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.070 Biomarker disease BEFREE A recent Phase II clinical trial demonstrated that administration of an FGF21 analogue significantly reduced hepatic fat in subjects with NASH. 31672443 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.070 Biomarker disease BEFREE FGF21-based drugs induce weight loss and improve dyslipidemia in patients with obesity and T2D, and reduce steatosis in patients with NASH. 30893110 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.070 Biomarker disease BEFREE Plasma FGF21 was higher in patients with NASH (453 ± 262 pg/mL) when compared with the No NASH (341 ± 198 pg/mL, P = 0.03) or No NAFLD (325 ± 289 pg/mL, P = 0.02) groups. 30848827 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.070 Biomarker disease BEFREE Reduced Oxidative Stress and Enhanced FGF21 Formation in Livers of Endurance-Exercised Rats with Diet-Induced NASH. 31717358 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.070 Biomarker disease BEFREE Here, we have explored the effects of PsTag600-FGF21, an engineered long-acting FGF21 fusion protein, in mice with NASH and describe some of the underlying mechanisms. 29859019 2018
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.070 Biomarker disease BEFREE The results suggest that increased circulating CK-18 and FGF-21 are associated with NASH and may be used for initial assessment, but not enough. 28326329 2017
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.070 AlteredExpression disease BEFREE Serum FGF21 and hepatic mRNA expression were measured in obese individuals with NAFLD or NASH. 20451522 2010